Search the Newsreel

Fulgent Genetics, Inc. $FLGT Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP significantly increased its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 374.7% in the first quarter, bringing its total holdings to 137,479 shares valued at $2.19 million. Institutional investors now own 48.06% of FLGT, while company insiders hold 36.18%, with recent …

Discipline and Rules-Based Execution in FLGT Response

This article analyzes Fulgent Genetics Inc. (NASDAQ: FLGT), highlighting a near-term strong sentiment despite persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and an exceptional 98.2:1 risk-reward setup, targeting a 28.2% gain versus 0.3% risk. The article details three AI-generated trading …

Fulgent Genetics, Inc. $FLGT Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP significantly reduced its stake in Fulgent Genetics (NASDAQ:FLGT) by 24.4% in the first quarter, selling over 217,000 shares. This comes as Fulgent Genetics reported a quarterly loss and revenue below analyst expectations, contributing to a "Hold" consensus rating among analysts. …

Wall Street Zen Downgrades Fulgent Genetics (NASDAQ:FLGT) to Strong Sell

Wall Street Zen has downgraded Fulgent Genetics (NASDAQ:FLGT) from a "sell" to a "strong sell" rating, despite a broader analyst consensus of "hold" with a $27.50 price target. This downgrade follows Fulgent's recent quarterly earnings report, which missed analyst expectations for both EPS and …

Price to sales forward of Fulgent Genetics, Inc. – MUN:7F0

This page from TradingView provides financial information for Fulgent Genetics, Inc. (MUN:7F0), specifically focusing on its forward price-to-sales ratio. The content appears to be a stub or a placeholder, as no specific values or detailed data regarding the price-to-sales metric are visible.

Fulgent Genetics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:FLGT) 2026-08-07

This article presents the slide deck published by Fulgent Genetics, Inc. in conjunction with their Q2 2026 earnings call. The content is provided by Seeking Alpha's transcripts team, which publishes numerous quarterly earnings calls. The aim is to share transcript-related developments with readers.

Noticias de acciones de Fulgent Genetics Inc (FLGT)

Fulgent Genetics, Inc. (FLGT) Stock Price, News, Quote & History

This article provides a comprehensive overview of Fulgent Genetics, Inc. (FLGT), including its stock price, historical data, company profile, and financial performance. As of August 7, the stock closed at $19.14, up 3.18%. The company specializes in clinical diagnostic and therapeutic development solutions, offering …

Fulgent Genetics (FLGT) Stock Gets Fair Value Boost After Analysts Raised Targets

FULGENT GENETICS INC : PIPER SANDLER RAISES TARGET PRICE TO $19.00 FROM $15.00

Piper Sandler has raised its target price for Fulgent Genetics Inc (FLGT.O) shares to $19.00 from $15.00. This update indicates a more optimistic outlook from the analyst firm regarding the company's future stock performance. The report was issued by Reuters on August 4, 2026.

Fulgent Genetics Inc (7F0) Q1 2024 Earnings Report - Results, Call & Slides

Fulgent Genetics Inc (7F0) has released its Q1 2024 earnings report, showing an actual EPS of -€0.01, beating the consensus EPS of -€0.28. The company's revenue for the quarter was €55.93M, missing the expected €56.69M, and showing a YoY revenue growth decline of 2.54%. …

Fulgent Genetics, Inc. (NASDAQ:FLGT) Receives Consensus Recommendation of "Hold" from Analysts

Analysts have issued a "Hold" consensus recommendation for Fulgent Genetics (NASDAQ:FLGT), with an average 12-month price target of $27.00. The company recently reported Q2 2026 revenue of $85.4 million, missing estimates, and a non-GAAP loss of $0.58 per share, which exceeded expectations. Management also …

Fulgent Genetics (NASDAQ:FLGT) Announces Quarterly Earnings Results

Fulgent Genetics (NASDAQ:FLGT) reported disappointing quarterly earnings, missing analyst estimates for both EPS and revenue due to revenue-cycle issues, including delayed billing and lower collection rates. The company also reduced its full-year 2026 guidance, forecasting lower revenue and negative non-GAAP EPS. Despite these setbacks, …

Fulgent Genetics (FLGT) Stock Price Slides As Losses Deepen Guidance Falls

Fulgent Genetics (FLGT) saw its stock price fall by approximately 18% after reporting a significant quarterly net loss of US$29.5 million and lowering its full-year guidance. The company's revenue increased slightly year-on-year, but profitability challenges persist, with widening losses and reduced non-GAAP gross margins. …

Fulgent Genetics Inc reports results for the quarter ended June 30 - Earnings Summary

Fulgent Genetics Inc (FLGT) has released its earnings summary for the quarter ended June 30. The report, provided by Refinitiv, gives an overview of the company's financial performance. Full access to the article is available through a TradingView subscription.

Fulgent Genetics cuts FY26 revenue guidance amid billing delays

Fulgent Genetics reported Q2 2026 revenue of $85.4 million and a non-GAAP loss of $16.2 million, missing analyst estimates. The company lowered its full-year 2026 revenue guidance to $330-$340 million and non-GAAP loss to $63-$67 million, attributing the revisions to delays in its billing …

Fulgent Genetics Q2 Earnings Call Highlights

Fulgent Genetics reported second-quarter 2026 revenue of $85.4 million, a 20% sequential increase, but faced challenges from billing system transition issues that pressured collections and gross margins, leading to a $29.5 million GAAP net loss. The company lowered its 2026 revenue guidance to $330 …

Fulgent Genetics (NASDAQ:FLGT) Updates FY 2026 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) has updated its FY 2026 earnings guidance, projecting an EPS of -$2.35 to -$2.22 and revenue of $330 million to $340 million, which falls below consensus estimates. The company also missed Q2 earnings expectations, reporting an adjusted EPS of -$0.58 and …

Fulgent Genetics earnings missed by $0.14, revenue fell short of estimates

Fulgent Genetics (FLGT) Earnings Date and Reports 2026 $FLGT

Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Misses Revenue Estimates

Fulgent Genetics (FLGT) Releases Q2 2026 Earnings: Revenue Growth but EPS Miss

Fulgent Genetics Inc (FLGT) Financial Health: Profitability & Balance Sheet Analysis

Fulgent Genetics Inc (FLGT) currently holds a financial score of 6.89, placing it 52nd out of 75 in the Healthcare Providers & Services industry, indicating stable financial health and high operating efficiency. Despite this, its latest quarterly revenue decreased by 3.16% year-over-year to $71.14M, …

Behavioral Patterns of FLGT and Institutional Flows

This article analyzes behavioral patterns and institutional flows for Fulgent Genetics Inc. (NASDAQ: FLGT), suggesting a near-term neutral sentiment that may pause mid- and long-term weakness. It highlights an exceptional 96.0:1 risk-reward setup targeting a 26.9% gain with minimal risk. The report also provides …

Fulgent Genetics Inc (FLGT) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Fulgent Genetics Inc (FLGT), noting its score of 6.80, which ranks 25 out of 75 in the Healthcare Providers & Services industry. The company's beta of 0.93 indicates it tends to underperform in up markets but decline …

Fulgent Genetics Inc expected to post a loss of 46 cents a share - Earnings Preview

Fulgent Genetics Inc (FLGT) is projected to report a loss of 46 cents per share in its upcoming earnings announcement. This preview indicates the anticipated financial performance for the company, suggesting a negative earnings per share.

Fulgent Genetics CSO Gao Hanlin Executes Tax-Related Sale of 1,645 Shares at $19.67 on July 26, 2026

Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, Inc. (NASDAQ: FLGT), sold 1,645 common shares at $19.67 each on July 26, 2026, to cover tax obligations. Following this transaction, Hanlin still directly owns 988,729 common shares in the genomics testing company. The sale was …

Fulgent Genetics Inc (FLGT) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Fulgent Genetics Inc (FLGT), covering operating, investing, and financing activities. It presents financial data including net income, capital expenditures, and changes in working capital over several years. The report also includes FAQs …

Fulgent Genetics Inc (FLGT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Fulgent Genetics Inc (FLGT) stock, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. The page displays various financial metrics and stock performance data …

Fulgent Genetics Inc (FLGT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Fulgent Genetics Inc (FLGT), categorized by business segments and regional contributions. For specific financial periods, it indicates the revenue proportions from Institutional, Insurance, and Patient segments, as well as from the United States and Foreign regions. …

FLGT|Fulgent Genetics Inc|Price:19.670|Chg%:-0.310

Fulgent Genetics Inc (FLGT) trades at $19.670, showing a -1.55% change. The company has healthy fundamentals and significant growth potential, although its valuation is considered fairly valued within the Healthcare Providers & Services industry. One analyst rates FLGT as "Hold" with a target price …

Fulgent Genetics, Inc. Revenue Breakdown – FWB:7F0

Fulgent Genetics, Inc. (FWB:7F0) generated €274.73 million in revenue last year, with its Laboratory Services segment contributing the most at €274.35 million. The majority of the revenue, €252.49 million, originated from the United States. This financial overview highlights the company's key revenue streams and …

Fulgent Genetics (FLGT) to Release Earnings on Thursday

Fulgent Genetics (FLGT) is scheduled to release its Q2 2026 earnings before market open on Thursday, July 30th, with analysts anticipating a loss of $0.46 per share on revenues of $94.0 million. Wall Street maintains a "Hold" rating for FLGT with a consensus price …